Regulation of pituitary adenylyl cyclase-activating polypeptide (PACAP, ADCYAP1: adenylyl cyclase-activating polypeptide 1) in the treatment of schizophrenia.
BACKGROUND
Deficiency of pituitary adenylyl cyclase-activating polypeptide (PACAP) and its specific receptor, PAC1, causes a schizophrenia-like phenotype in mice. In addition, the relation of the PACAP and PAC1 genes to schizophrenia has been shown by single-nucleotide polymorphism association studies. Furthermore, PACAP is reported to be involved in the function of disrupted-in-schizophrenia 1.


OBJECTIVE
To summarize briefly the recent evidence relating the PACAP system and schizophrenia and discuss the application of PACAP to the treatment of schizophrenia.


CONCLUSIONS
The regulation of PACAPergic signals is an interesting potential treatment for schizophrenia. Further studies of PACAP signals and the association of PACAP signals with schizophrenia should shed the light on the utility of this approach in the treatment of schizophrenia.
Matsuzaki
Shinsuke
S
Osaka University, The Osaka-Hamamatsu Joint Research Center for Child Mental Development, Graduate School of Medicine, Department of Anatomy and Neuroscience, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. s-matsuzaki@anat2.med.osaka-u.ac.jp
Tohyama
Masaya
M
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D006801:Humans; D051379:Mice; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide / Q000819:agonists* / Q000378:metabolism*; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism*
D014150:Antipsychotic Agents; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide